Actelion Ltd.
Description Actelion Ltd, a biopharmaceutical company, engages in the discovery, development, and commercialization of low molecular weight drugs for unmet medical needs. Its products include Tracleer, a dual endothelin receptor antagonist for the treatment of pulmonary arterial hypertension (PAH), a chronic and life-threatening disorder that severely compromises the functions of the lungs and heart; and Veletri, a formulation of epoprostenol for the treatment of PAH. The companys products also comprise Ventavis, an inhaled formulation of iloprost for the treatment of PAH; and Zavesca, an oral treatment for adult patients with mild to moderate type 1 Gaucher disease for whom enzyme replacement therapy is unsuitable. Actelion Ltd markets its products primarily in Switzerland, the United States, and other countries. The company was founded in 1997 and is headquartered in Allschwil, Switzerland. To view the detailed information, you need to SUBSCRIBE with us. |
 |